Erasca Foundation Files Intent to Sell $20.6k in ERAS Stock
Erasca, Inc.
Subscribe to track ERAS
Premium users can add ticker alerts and receive realtime notification updates.
Filing Summary
Erasca Foundation Files Intent to Sell $20.6k in ERAS Stock
Company: Erasca, Inc. (ERAS) Form: 144 | Filed: 2025-10-15 Significance: Low
Insider: Erasca Foundation Title: null | Relationship: Affiliate (Foundation)
Transaction: • Type: Proposed Sale (Form 144) • Shares: 8,333 • Approx. Value: $20,591.33 • Approx. Price: $2.47 • Sale Date: ~2025-10-15
Key Insight: This is a small, pre-planned sale by the company's foundation, filed under a 10b5-1 plan adopted in January 2024. It follows a pattern of identical monthly sales, indicating it's for liquidity rather than a reaction to market conditions.
This is PUBLIC SEC data for educational purposes. Not investment advice.
Comprehensive Analysis
SEC Filing Analysis: Erasca, Inc. (ERAS)
Executive Summary
- Trading Significance: Low
- Key Takeaway: The Erasca Foundation has filed a notice of proposed sale for 8,333 shares of common stock, valued at approximately $20,591. This transaction is being conducted under a pre-arranged Rule 10b5-1 trading plan, indicating it is a scheduled liquidity event rather than a strategic decision based on current company performance.
- Market Impact: The market impact is expected to be neutral. The small size of the transaction and its programmatic nature (part of a 10b5-1 plan) mean it carries little to no new information for investors.
Company Information
| Field | Value |
|---|---|
| Company | Erasca, Inc. |
| Ticker Symbol | ERAS |
| CIK | 0001761918 |
| Industry | Pharmaceutical Preparations |
Insider Information
| Field | Value |
|---|---|
| Name | Erasca Foundation |
| CIK | 0001973524 |
| Title/Position | null |
| Relationship | Affiliate of the Issuer |
Transaction Details
| Field | Value |
|---|---|
| Form Type | 144 (Notice of Proposed Sale) |
| Transaction Date | ~2025-10-15 (Approximate Sale Date) |
| Transaction Code | Not Applicable (Form 144) |
| Security Type | Common Stock |
| Shares Involved | 8,333 |
| Price Per Share | ~$2.47 (Calculated from Aggregate Market Value) |
| Total Value | $20,591.33 |
| Shares Owned After | Not specified |
| Ownership Type | Not specified |
Market Impact Analysis
Stock Impact Prediction
- Direction: Neutral
- Reasoning: This filing is a Form 144, a notice of intent to sell, not a completed sale. The value is minimal relative to the company's market capitalization. Most importantly, the filing explicitly notes a plan adoption date of January 10, 2024, confirming this is a pre-scheduled 10b5-1 sale. Such plans are established when insiders are not in possession of material non-public information, and the subsequent sales are automated.
Volume & Sentiment
- Expected Volume Impact: Negligible. The 8,333 shares represent a tiny fraction of the daily trading volume.
- Sentiment Indicator: Neutral. The market generally disregards small, programmatic sales from foundations or under 10b5-1 plans as they are not indicative of an insider's outlook on the company's future.
Investment Insights
Positive Market Indicators
- The existence of a structured 10b5-1 plan for the foundation's dispositions demonstrates orderly and transparent liquidity management.
Risk Factors
- This specific filing poses no new risk. The primary risks are associated with the company's underlying business in the highly competitive pharmaceutical industry.
Key Takeaways
- Programmatic Sale: The sale is part of a Rule 10b5-1 trading plan adopted on January 10, 2024.
- Recurring Pattern: The filing discloses identical sales of 8,333 shares in September, August, and July 2025, confirming a consistent, automated selling schedule.
- Low Signal Value: Sales from foundations are typically for operational funding or charitable purposes and do not reflect the strategic sentiment of key executives. This, combined with the 10b5-1 plan, gives the transaction very low informational value.
Contextual Analysis
Timing Significance
The timing is dictated by the pre-set schedule of the 10b5-1 plan, not by any specific market event or internal company development. The filing is a procedural requirement.
Transaction Context
The shares were originally acquired by the foundation via a donation from Erasca, Inc. on July 20, 2021. The foundation is now systematically liquidating small portions of this holding, likely to fund its operations, as evidenced by the consistent monthly sales.
Company Context
Erasca, Inc. operates in the pharmaceutical preparations sector. Analysis of this filing should be viewed in the broader context of the company's clinical trial progress, financial health, and competitive landscape, none of which are influenced by this minor transaction.
Risk Assessment
Risk Level: Low
Risk Factors
- The transaction itself presents no material risk to investors.
- The sale is not being made by a key executive (CEO, CFO, etc.), reducing its significance.
- The amount is de minimis.
Market Considerations
- Investors should focus on fundamental company metrics (e.g., drug pipeline, earnings reports, cash burn) rather than this procedural filing.
- The transparency of the 10b5-1 plan can be seen as a positive governance practice.
IMPORTANT DISCLAIMER: This analysis is for informational purposes only and is not intended as investment advice. The information presented is based on publicly available SEC filings and should not be construed as a recommendation to buy, sell, or hold any securities. Past performance does not guarantee future results. All investments carry risk, including the potential loss of principal. Please consult with a qualified financial advisor before making any investment decisions.
Analysis generated on 2025-10-15 | Data source: SEC EDGAR
Get Real-Time Alerts
Join our community to receive instant notifications when high-significance filings are published
Important Disclaimer
This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.
Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.